LUNG Stock Analysis: Buy, Sell, or Hold?
LUNG - Pulmonx Corporation Common Stock
$1.28
0.01 (0.79%)
▲
5d:
+0.0%
30d:
-16.88%
90d:
-7.91%
BUY
HIGH Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Jul 29, 2026
Get Alerted When LUNG Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: LUNG shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
✅ BUY SIGNAL: LUNG shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
In-depth Analysis How we analyze
Valuation Analysis: LUNG is currently trading at $1.28, which is considered oversold relative to its 30-day fair value range of $1.31 to $1.59.
Technical Outlook: Technically, LUNG is in a downtrend. The price is currently testing key support at $1.45. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $3.40 (+165.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, LUNG is in a downtrend. The price is currently testing key support at $1.45. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $3.40 (+165.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.31 -
$1.59
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
86.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 165.6% below Wall St target ($3.40)
Trading Range Analysis
30-Day Trading Range
$1.31 -
$1.59
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$0.22
(16.8%)
Support & Resistance Levels
Support Level
$1.45
Resistance Level
$1.72
Current Trend
Downtrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.23
Wall Street Target
$3.40
(+165.6%)
Revenue Growth (YoY)
-8.7%
Profit Margin
-60.1%
Share & Embed Analysis
Last updated: June 23, 2026 6:29 PM ET
Data refreshes hourly during market hours. Next update: 7:29 PM
Data refreshes hourly during market hours. Next update: 7:29 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is LUNG showing a specific setup today?
Insider Activity (6 Months)
0
Buys
4
Sells
Net
INSIDERS SELLING
Recent Transactions
Geoffrey Beran Rose
SELL
7732 shares
2026-03-02
Glendon E French III
SELL
67813 shares
2026-03-02
Srikanth Radhakrishnan
SELL
10483 shares
2026-03-02
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$77 | 60 HOLD |
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$85 | 57 HOLD |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$387 | 61 BUY |
|
PODD
Insulet Corporation |
STRONG BUY
24 analysts |
$242 | 61 BUY |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$117 | 59 HOLD |
